{"id":"NCT01520909","sponsor":"GlaxoSmithKline","briefTitle":"Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.","officialTitle":"A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2012-01-30","resultsPosted":"2014-09-29","lastUpdate":"2015-03-10"},"enrollment":92,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Thrombocytopenic Purpura"],"interventions":[{"type":"DRUG","name":"Eltrombopag","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Eltrombopag plus standard of care","type":"EXPERIMENTAL"},{"label":"Placebo plus standard of care","type":"PLACEBO_COMPARATOR"},{"label":"Eltrombopag plus standard of care (Part 2 open-label)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study. In part 1, patients will be randomized to receive either eltrombopag or placebo for 13 weeks. All patients who complete part 1 will enter part 2. In part 2, all patients will receive 24 weeks of eltrombopag.","primaryOutcome":{"measure":"Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1","timeFrame":"From Week 5 up to Week 12 of Part 1","effectByArm":[{"arm":"Part 1 (Randomized Period)- Placebo","deltaMin":1,"sd":null},{"arm":"Part 1 (Randomized Period)-Eltrombopag","deltaMin":25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":20,"exclusionCount":13},"locations":{"siteCount":51,"countries":["United States","Argentina","Czechia","Germany","Hong Kong","Israel","Italy","Poland","Russia","Spain","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["29536526","26231455"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":63},"commonTop":["Epistaxis","Nasopharyngitis","Upper respiratory tract infection","Headache","Rhinitis"]}}